SCHEMBL24312255

SCHEMBL24312255

CC(C)(C#Cc1cc(Cl)cc(N2CCOCC2)n1)NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 1/20 0.39
▸ RAF1 P04049 4/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ KIF18A Q8NI77 2/20 0.37
▸ MAPT P10636 2/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ BRAF P15056 1/20 0.35
▸ SUV39H2 Q9H5I1 3/20 0.35
▸ PIK3CA P42336 1/20 0.35
▸ ACACB O00763 1/20 0.35
▸ ACACA Q13085 1/20 0.35
▸ ATR Q13535 1/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24312197 0.86 AKT1 (0.43) AKT1RAF1KMT2AKIF18AMAPT
SCHEMBL24312208 0.84 KIF18A (0.40) AKT1RAF1KMT2AKIF18AMAPT
SCHEMBL24312272 0.82 RAF1 (0.40) AKT1RAF1KMT2AKIF18AMAPT
SCHEMBL24312333 0.77 RAF1 (0.40) AKT1RAF1KIF18A
SCHEMBL24312275 0.76 CYP1A2 (0.36) RAF1KIF18ACYP1A2ATR
SCHEMBL23299990 0.73 GAA (0.41) AKT1RAF1KMT2AKIF18AMAPT
SCHEMBL29762501 0.73 GAA (0.41) AKT1RAF1KMT2AKIF18AMAPT
SCHEMBL23275378 0.73 GAA (0.41) AKT1RAF1KMT2AKIF18AMAPT
SCHEMBL24312188 0.72 MAPT (0.39) AKT1KMT2AKIF18AMAPTMEN1
SCHEMBL24312182 0.72 KMT2A (0.46) KMT2AMAPTKDM4EMEN1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-11746095-B2 Inhibtors of RAF kinases KINNATE BIOPHARMA INC. (US) 2023-09-05 — — US disclosed
US-20220356160-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-11-10 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
US-11377431-B2 Inhibitors of RAF kinases KINNATE BIOPHARMA INC. (US) 2022-07-05 — — US disclosed
WO-2022081469-A1 INHIBITORS OF RAF KINASES KINNATE BIOPHARMA INC. (US) 2022-04-21 — — WO disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed
US-20220112170-A1 INHIBITORS OF RAF KINASES Pierre Fabre Médicament (FR) 2022-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220112170-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF AKT1 38/4885RAF1 2/4885KMT2A 1631/4885
US-11746095-B2 Inhibtors of RAF kinases RAF1, BRAF, ARAF AKT1 38/4885RAF1 1/4885KMT2A 2824/4885
US-20220356160-A1 INHIBITORS OF RAF KINASES BRAF, RAF1, ARAF AKT1 38/4885RAF1 2/4885KMT2A 1631/4885
US-11377431-B2 Inhibitors of RAF kinases BRAF, RAF1, ARAF AKT1 38/4885RAF1 2/4885KMT2A 1631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback